The anti-tumor effects of deltarasin were also validated and confirmed in vivo applying an orthotopic HCC mouse model and KRAS inhibition by deltarasin markedly enhanced sorafenib-induced tumor cell apoptosis and inhibition of proliferation in HCC cells [109]. Here, KRAS is linked to hepatocellular carcinoma.